Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOX
Raymond Debbane reported a 9.99% stake in Eloxx Pharmaceuticals, Inc. (Schedule 13G)
Event Jun 9, 2026 · Filed Jun 15, 2026
Raymond Debbane reported a 9.99% stake in Eloxx Pharmaceuticals, Inc., 403,586 shares, as a passive investor on Jun 9, 2026. Filed Jun 15, 2026 (Schedule 13G).
- Stake
- 9.99%
- Shares
- 403,586
- Intent
- Passive
- What changed
- Crossed above 5%
- Filed together
- 8 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Invus Public Equities, L.P. | 8.80% | 353,667 |
| Invus Public Equities Advisors, LLC | 8.80% | 353,667 |
| Invus Global Management, LLC | 8.80% | 353,667 |
| Siren, L.L.C. | 8.80% | 353,667 |
| Avicenna Life Sci Master Fund LP | 1.20% | 49,919 |
| Avicenna Life Sci Master GP LLC | 1.20% | 49,919 |
| Ulys, L.L.C. | 1.20% | 49,919 |
| Raymond Debbane | 9.99% | 403,586 |
Source
Related
- Eloxx Pharmaceuticals, Inc.
- Invus Public Equities, L.P.
- Eloxx Pharmaceuticals, Inc. shareholders
- Schedule 13G · Nantahala Capital Management, LLC · Aug 14, 2026
- Schedule 13G · Srinivas Akkaraju · Aug 14, 2026
- Schedule 13G · Domicilium Capital Partners LLC · Jun 17, 2026
- Schedule 13G · EcoR1 Capital, LLC · Jun 16, 2026
- Schedule 13G · Stonepine Capital Management, LLC · Jun 16, 2026